Short answer
Scholar Rock Holding Corp (SRRK) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$106M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$106M
- −41.2% YoY
- EPS (diluted)
- −$0.83
- −23.9% YoY
Source: XBRL data from the Scholar Rock Holding Corp (SRRK) Q1 2026 10-Q on SEC EDGAR. USD.
Scholar Rock Holding Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0; no product sales, unchanged from prior year
- Net loss $105.5M vs $74.7M YoY; operating expenses $102.0M vs $77.1M
- R&D expense $51.8M vs $48.7M; apitegromab largest program at $20.3M
- Cash, equivalents and securities $479.9M vs $367.6M; operating cash outflow $82.1M
- Outlook: September 30, 2026 FDA action date; continued substantial development and commercialization spending
Risk Factors
- FDA CRL triggered by third-party fill-finish facility inspection; BLA resubmitted March 2026 with September 30, 2026 PDUFA date
- EMA MAA approval risk from FDA OAI classification; potential CHMP refusal if GMP non-compliance remains unresolved
- Government agency disruption risk from 2025 FDA staffing and resource reductions, potentially delaying BLA review
- Commercialization execution risk from no prior sales or distribution experience and limited market-access capabilities
- Manufacturing supply concentration risk from reliance on a limited number of third-party suppliers for clinical and commercial materials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Scholar Rock Holding Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.